DIACCURATE
DIACCURATE, a French biotechnology company that develops sole-in-class therapeutics in immunotherapy, oncology and infectiology today announced the formation of its Scientific Advisory Board (SAB). Composed of 6 independent world-leading experts in the fields of basic and translational immunology, lipid metabolism, oncology and immunotherapy DIACCURATE’s SAB is chaired by Professor Tasuku HONJO, Kyoto University’s Institute for Advanced Study (KUIAS), awarded by the 2018 NOBEL PRIZE in Physiology or Medicine for his discovery of "immune checkpoint inhibitors", a key step in the history of cancerology.
Dr. Dominique BRIDON, CEO of DIACCURATE , commented: "We feel honored to have gathered this world-renowned group of experts in our newly formed Scientific Advisory Board around Prof. Jacques THÈZE, CSO and Scientific co-Founder of DIACCURATE”. He added: “We look forward to building on their exceptional knowledge and complementary experience in immunology, immunotherapy and oncology to progress our highly original and ambitious pipeline towards the clinic.”
“Cancer treatment has seen a revolution in immunotherapy. Extensive research to which my lab has contributed has brought to light the importance of cytotoxic CD8 T cells in the antitumor immune response, giving rise to current immune checkpoint inhibitors. But the role of CD4 T cells in this response had so far remained overlooked”, said Prof. Tasuku HONJO, Deputy Director-General of KUIAS and Chairman of DIACCURATE’s SAB . He explained: “Recent findings have demonstrated the key contribution of CD4 T cells to clinical efficacy of PD-L1/PD-1 blockade therapies.The developments undertaken at DIACCURATE to boost CD4 T cells functionality could represent a major step towards improving immunotherapy.”
Prof. Christoph HUBER, co-founder of the mRNA vaccine pioneer BioNTech, board member of the International Association of Cancer Immunotherapy and member of DIACCURATE’s SAB , added: “As we have seen once again with the COVID-19 pandemic, vaccines are an unvaluable immunotherapy tool to prevent and treat diseases that affect the immune system. It has been well known for over a century in the field of infectious diseases, it is also becoming an evidence in the field of oncology, and strategies like that of DIACCURATE that potentiate CD4 T cells response are expected to further improve the efficacy and the profile of vaccines”.
Dr. Bernard MALISSEN, Founder and Director of the Center for Immunophenomics, team leader and former Director of the Centre d'Immunologie de Marseille Luminy and member of DIACCURATE’s SAB , concluded: “Intricate biological networks control physiological and pathologic processes and revolve around biological switches. By integrating incoming signals and determining the downstream pathways that need to be activated, they constitute key “decision makers”. DIACCURATE has laid solid foundations to take on the challenge of targeting such biological switches, which are of tremendous importance in various pathological contexts, including cancer and infectious diseases”.
DIACCURATE
DIACCURATE is a late preclinical stage biotechnology company that invests the new frontiers of immunotherapy and oncology, firstly CD4 immunotherapy and targeted chemotherapy. At the forefront of translational medicine, these sole-in-class drug candidates target incurable diseases: refractory acute myeloid leukemia, pancreatic cancer and AIDS. DIACCURATE is conducting 3 proprietary development programs and expects to start its first clinical trial by 2022.
DIACCURATE is supported by a high-level management team led by Dr. Dominique BRIDON and world-class Board of Directors and Scientific Advisory Board chaired by Dr. Philippe POULETTY, CEO of TRUFFLE, and Prof. Tasuku HONJO, 2018 Nobel Prize in Medicine.
For more information, visit www.diaccurate.com and follow @DiaccurateTx
TRUFFLE CAPITAL
Created in 2001, TRUFFLE CAPITAL is an independent European Venture Capital company, specialising in life sciences (MedTech and Biotech) and in breakthrough IT technologies (FinTech and InsurTech). The mission of TRUFFLE CAPITAL is to help the creation and development of young innovating companies, capable of becoming tomorrow’s leaders.
Chaired by Patrick KRON and led by Dr. Philippe POULETTY et Bernard-Louis ROQUES, co-founders and CEOs, TRUFFLE CAPITAL has raised over €1.1 billion since its inception and helped over 70 companies in the digital technology and life sciences sectors. In 2019, TRUFFLE CAPITAL announced having raised almost €400 million in new institutional funds, including €250 million for new BioMedTech investments.
For more information, visit www.truffle.com and follow @trufflecapital
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005604/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Files FERC Application for Plaquemines Expansion Project18.11.2025 00:02:00 CET | Press release
Today, Venture Global, Inc. (NYSE: VG) filed with the Federal Energy Regulatory Commission (FERC) its application for the permitting and approval of the Plaquemines LNG brownfield expansion project. In addition, Venture Global has filed with the U.S. Department of Energy (DOE) for the export authorizations associated with this expansion. The Plaquemines Expansion was announced earlier this year with U.S. Secretary of Energy Chris Wright, U.S. Secretary of the Interior Doug Burgum, and Louisiana Governor Jeff Landry. Venture Global has since increased the expected output from this project by nearly 40% from the previously announced plans due to the continued optimization of our liquefaction trains and strong market demand. This bolt-on expansion will be built incrementally in three phases and consist of 32 modular liquefaction trains, adding in total over 30.0MTPA in peak production capacity. This will bring the total peak production capacity across the entire Plaquemines complex to ove
Global EV Alliance Releases EV Driver Survey Results: Myths Are Slowing EV Market17.11.2025 19:19:00 CET | Press release
In a groundbreaking survey of more than 26,000 EV drivers across 30 countries, an overwhelming 77% say persistent myths about electric cars are the single biggest obstacle to EV adoption in their nations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118388193/en/ There are still significant differences in the EV market across countries, and not everyone has a wide range of car brands to choose from. Photo: Markus Rotevatn/Norwegian EV Association. 83% say they believe policy measures are needed to increase EV sales in their country. “Misinformation about EVs is a serious challenge. It can make policymakers less confident that electric vehicles are a viable solution to climate change and local air pollution,” says Joel Levin, chair of GEVA and Director of Plug in America. One common myth in many countries is that electric cars are a fire hazard. 88% of the EV drivers in the survey say they aren’t worried about their EV b
Dilawer Farazi Returns to Loomis Sayles as Co-Head and Portfolio Manager on the Emerging Markets Debt Team17.11.2025 16:59:00 CET | Press release
Loomis, Sayles & Company is pleased to announce that Dilawer Farazi, ACA, has rejoined the firm as Co-Head and Portfolio Manager of the Emerging Markets Debt (EMD) Team. Dilawer becomes the firm’s first London-based portfolio manager. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117681347/en/ Dilawer Farazi, ACA, has rejoined Loomis Sayles as Co-Head and Portfolio Manager of the Emerging Markets Debt Team Dilawer brings over two decades of experience in emerging markets credit, having previously served as a Senior Credit Research Analyst at Loomis Sayles from 2018 to 2020. He rejoins the firm from Royal London Asset Management (RLAM), where he led the Emerging Markets Credit team and managed approximately USD $1 billion in assets across EM credit. At RLAM, he launched the firm’s first dedicated emerging markets funds, including an emerging markets corporate bond fund and an emerging markets short duration credit fund. I
Duravant Announces Retirement of CEO Mike Kachmer, Names Jill Evanko Successor17.11.2025 16:13:00 CET | Press release
Mike Kachmer to retire following a distinguished 43-year career, including nearly 12 years as Chairman & CEO of Duravant Jill Evanko to succeed Mr. Kachmer as Duravant’s Chief Executive Officer Duravant LLC (“Duravant”), a global leader in advanced automation solutions, announced today that Mike Kachmer will retire from his role as Chief Executive Officer after a highly successful tenure with the company. Duravant’s Board of Directors has named Jill Evanko as CEO, joining the company on January 5, 2026. To ensure a seamless transition, Mr. Kachmer will continue to serve as Chairman of Duravant. Mr. Kachmer will also continue to serve on the Board of Directors for Northwestern Memorial Healthcare and The London Clinic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117036720/en/ Mike Kachmer “It has been a true honor and a humbling experience to lead this incredible company,” said Mr. Kachmer. “I am profoundly grateful to
Wolters Kluwer Enablon Control of Work Solution Now Available as Private Offer in AWS Marketplace17.11.2025 15:00:00 CET | Press release
Wolters Kluwer today announced that its Enablon Control of Work solution is now available in AWS Marketplace as a private offer. This purchasing model empowers customers to negotiate and receive tailored pricing, terms, and licensing agreements, while streamlining procurement and leveraging existing Amazon Web Services (AWS) billing workflows to accelerate deployment and optimize cloud budgets. Wolters Kluwer’s Enablon Control of Work solution consolidates permit-to-work, isolation management and risk assessments into an integrated system. Trusted by frontline workers and contractors in high-risk environments including oil & gas, pharmaceuticals, data center and manufacturing industries, the software helps streamline operations, minimize unplanned downtime and prevent serious injuries and fatalities. Richard Pulliam, SVP & General Manager of EHS & ESG for Wolters Kluwer, said: “Making Enablon's Control of Work solution available in AWS Marketplace is another step in our mission to help
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom